What is Liraglutide?
Liraglutide is a GLP-1 receptor agonist built from a 31-amino-acid GLP-1 backbone with a C16 palmitic acid chain hung off a glutamic acid spacer. The fatty acid makes the molecule self-associate at the injection site and bind albumin once absorbed, which slows release and blocks DPP-4 cleavage. Measured elimination half-life in humans is approximately 13 hours — long compared with native GLP-1’s few minutes, short compared with anything on the weekly ladder.
That number sets the whole protocol. Liraglutide is a daily compound, escalated 0.6 -> 1.2 -> 1.8 -> 2.4 -> 3.0mg at roughly one step per week, which is structurally a different exercise from the once-weekly cadence of semaglutide, tirzepatide, or retatrutide. Seven injections a week instead of one changes handling, vial turnover, and how you plan material. Older searches still surface it under the trade names Saxenda and Victoza; same molecule.
The 10mg vial exists because of that cadence. It is the size that actually carries a maintenance-dose researcher through a useful stretch of days rather than a long weekend.
Reconstitution
Liraglutide reconstitutes with bacteriostatic water. Draw 2mL down the inside wall of the vial, swirl gently until the solution is clear, and refrigerate. Do not shake — the acylated backbone behaves like a surfactant and foams easily.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 10mg |
| Reconstitution Solvent | Bacteriostatic water |
| Recommended Volume | 2mL |
| Resulting Concentration | 5.00mg/mL |
| Typical Research Dose | 0.6-3.0mg |
| Frequency | daily |
| Reported Half-Life | ~13 hours (human) |
Reconstitution Guide
Materials Needed
- Liraglutide 10mg lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (U-100, 29-31 gauge)
- Alcohol swabs
- Sharps container
Step-by-Step Instructions
- Prepare workspace — Clean environment, gather materials, thorough handwashing.
- Clean vial stoppers — Wipe both vials with alcohol swabs. Allow complete drying.
- Draw BAC water — Draw 2mL bacteriostatic water using a sterile syringe.
- Add to peptide — Inject slowly down the inside wall of the vial. Do not spray directly onto the powder.
- Dissolve — Allow a few minutes for complete dissolution. Gentle swirl only — no shaking, and expect foam if you rush it.
- Verify — Solution should be clear and colourless.
- Label and store — Note reconstitution date. Refrigerate immediately.
Dosage Protocol
Concentration Calculations
With 10mg peptide in 2mL BAC water:
- Concentration: 10mg / 2mL = 5.00mg/mL (5000mcg/mL)
- Per unit (U-100 syringe): 5.00 x 1000 / 100 = 50mcg per unit
At this concentration every rung of the daily ladder, including the 3.0mg top step, fits inside a single U-100 syringe. Run your exact vial and water combination through the peptide reconstitution calculator to rebuild this table for your setup.
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 0.6mg (600mcg) | 0.12mL | 12 units |
| 1.2mg (1200mcg) | 0.24mL | 24 units |
| 1.8mg (1800mcg) | 0.36mL | 36 units |
| 2.4mg (2400mcg) | 0.48mL | 48 units |
| 3.0mg (3000mcg) | 0.60mL | 60 units |
The trade-off is at the bottom of the ladder: 0.6mg is only 12 units, so measurement error on the opening week is proportionally larger than it would be from a 5mg vial at 2.50mg/mL, where the same dose reads 24 units.
Doses Per Vial
With seven injections a week instead of one, vial arithmetic is the practical constraint. Nominal doses from 10mg, before dead space and overfill:
| Daily Dose | Doses Per 10mg Vial | Days of Coverage |
|---|---|---|
| 0.6mg | 16 | ~16 days |
| 1.2mg | 8 | ~8 days |
| 1.8mg | 5 | ~5.5 days |
| 2.4mg | 4 | ~4 days |
| 3.0mg | 3 | ~3.5 days |
A standard escalation consumes about 4.2mg in the first week and 21mg per week once it reaches 3.0mg daily — roughly two 10mg vials a week at maintenance. That is the number worth internalising before planning anything long-running on this compound. Doses per vial, overfill and dead space covers why real-world counts usually come in slightly above the nominal figures.
Research Considerations
Mechanism
Liraglutide agonises the GLP-1 receptor and reproduces the incretin signal: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite signalling through hypothalamic pathways. Clearing in about 13 hours, it produces a daily peak-and-trough exposure curve rather than the flat plateau a weekly agonist maintains. That difference in exposure shape, not just in potency, is why daily and weekly GLP-1 protocols do not map onto each other by simple milligram conversion — see dose equivalence when switching between GLP-1s.
Human pharmacokinetics here are unusually solid for anything in this catalogue: Tmax 8-12 hours, absolute bioavailability around 55%, plasma protein binding over 98%, apparent volume of distribution around 13L, apparent clearance around 1.2 L/h. Elimination runs through general endogenous protein catabolism rather than one clearance organ, with only trace liraglutide-related material recovered in urine and faeces.
The efficacy record is human and large: the SCALE weight-management programme ran 3.0mg daily for 56 weeks in more than 3,700 participants, and LEADER ran cardiovascular outcomes in type 2 diabetes at up to 1.8mg daily. Both describe the pharmaceutical article under clinical conditions, which is a different object from research-grade powder.
Sourcing for Research
Liraglutide is stocked far less widely by research peptide suppliers than the weekly analogs, and availability moves around. Where it does appear, prefer suppliers providing third-party testing and certificates of analysis (COA) per batch, and confirm the COA characterises the acylated peptide rather than an unmodified GLP-1 fragment. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.
Storage Requirements
Lyophilized (Powder)
- Temperature: -20°C or colder
- Duration: 2+ years
- Conditions: Dry, dark, protected from moisture
Reconstituted
- Temperature: 2-8°C (refrigerated)
- Duration: 4 weeks
- Conditions: Protected from light, never freeze
Daily draws mean a 10mg vial is usually empty inside a fortnight, so the limiting factor is stopper punctures and sterile technique rather than the four-week window.
Safety Considerations
- Liraglutide is covered here as a research compound
- Research use only — not for human consumption
- Research-grade material is not equivalent to a pharmaceutical preparation
- Use sterile technique; never reuse needles or syringes
Scientific References
- Liraglutide injection prescribing information, clinical pharmacology section — elimination half-life ~13 h, Tmax 8-12 h, bioavailability ~55%, protein binding >98%. DailyMed.
- Pi-Sunyer X, et al. “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.” N Engl J Med. 2015;373(1):11-22.
- Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Front Endocrinol. 2019;10:155.
Last updated: 2026-07-21.
Disclaimer: This information is for educational and research purposes only. Research-grade liraglutide is not intended for human consumption. Always follow applicable laws and institutional guidelines.